Shockwave Medical (SWAV) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

7 analysts have issued 12-month price objectives for Shockwave Medical's stock. Their SWAV share price forecasts range from $251.00 to $330.00. On average, they anticipate the company's share price to reach $292.29 in the next twelve months. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

Shockwave Medical's stock was trading at $205.61 at the start of the year. Since then, SWAV stock has decreased by 0.1% and is now trading at $205.50.
View the best growth stocks for 2023 here.

Shockwave Medical saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,660,000 shares, an increase of 30.7% from the August 31st total of 1,270,000 shares. Based on an average daily volume of 524,000 shares, the short-interest ratio is currently 3.2 days.
View Shockwave Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our SWAV earnings forecast.

Shockwave Medical, Inc. (NASDAQ:SWAV) posted its quarterly earnings data on Monday, August, 7th. The company reported $0.76 EPS for the quarter, missing the consensus estimate of $0.85 by $0.09. The business had revenue of $180.17 million for the quarter, compared to analyst estimates of $173.79 million. Shockwave Medical had a trailing twelve-month return on equity of 47.48% and a net margin of 39.56%. The firm's revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 EPS.

ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Neuberger Berman Disrupters ETF (NBDS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Alger Mid Cap 40 ETF (FRTY), WisdomTree U.S. Growth & Momentum Fund (WGRO) and First Trust Health Care AlphaDEX Fund (FXH).

Shockwave Medical updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $725.00 million-$730.00 million, compared to the consensus revenue estimate of $716.10 million.

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shockwave Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (10.15%), BlackRock Inc. (9.90%), Artisan Partners Limited Partnership (3.13%), State Street Corp (2.77%), Geode Capital Management LLC (1.54%) and Allspring Global Investments Holdings LLC (1.30%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $205.50.

Shockwave Medical (NASDAQ:SWAV) has a market capitalization of $7.55 billion and generates $489.73 million in revenue each year. The company earns $216 million in net income (profit) each year or $6.42 on an earnings per share basis.

The company employs 1,001 workers across the globe.

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.